Jennifer E. Cook net worth and biography

Jennifer Cook Biography and Net Worth

Director of Denali Therapeutics

Jennifer Cook was previously the Chief Executive Officer of GRAIL.

Jennifer also spent time at Roche Pharmaceuticals/Genentech where she held a number of senior management positions, covering the full lifecycle of product development and commercialization. From 2013 to 2016 she was Head of Region Europe for Roche Pharmaceuticals, where she was responsible for the commercial success of Europe and leading more than 5,500 employees across the 28 countries of the region. Other key positions during her 25-year tenure at Roche/Genentech included leading Global Clinical Operations, US and Global Product Portfolio Management, a US Commercial Business Unit, and Market Development.

Jennifer started her career in research and early development at Genentech and a venture-backed startup company. In 2016, Jennifer was recognized for her contributions to the healthcare industry and inspirational leadership when she was named Woman of the Year by the Healthcare Businesswomen’s Association. Jennifer holds a BA in human biology and an MS in biology from Stanford University, as well as an MBA from the Haas School of Business at University of California, Berkeley.

What is Jennifer E. Cook's net worth?: The estimated net worth of Jennifer E. Cook is at least $495,740.12 as of June 6th, 2024. Ms. Cook owns 20,038 shares of Denali Therapeutics stock worth more than $495,740 as of December 3rd. This net worth approximation does not reflect any other investments that Ms. Cook may own. Learn More about Jennifer E. Cook's net worth.
How do I contact Jennifer E. Cook?: The corporate mailing address for Ms. Cook and other Denali Therapeutics executives is 161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA, 94080. Denali Therapeutics can also be reached via phone at (615) 866-8548 and via email at [email protected]. Learn More on Jennifer E. Cook's contact information.
Has Jennifer E. Cook been buying or selling shares of Denali Therapeutics?: Jennifer E. Cook has not been actively trading shares of Denali Therapeutics over the course of the past ninety days. Most recently, Jennifer E. Cook sold 1,458 shares of the business's stock in a transaction on Thursday, June 6th. The shares were sold at an average price of $21.73, for a transaction totalling $31,682.34. Following the completion of the sale, the director now directly owns 20,038 shares of the company's stock, valued at $435,425.74. Learn More on Jennifer E. Cook's trading history.
Who are Denali Therapeutics' active insiders?: Denali Therapeutics' insider roster includes Jennifer Cook (Director), Carole Ho (Insider), Steve Krognes (CFO), Vicki Sato (Director), David Schenkein (Director), Alexander Schuth (COO), Marc Tessier-Lavigne (Director), and Ryan Watts (CEO). Learn More on Denali Therapeutics' active insiders.
Are insiders buying or selling shares of Denali Therapeutics?: In the last twelve months, insiders at the sold shares 20 times. They sold a total of 276,160 shares worth more than $6,312,378.82. The most recent insider tranaction occured on November, 7th when insider Alexander O Schuth sold 15,558 shares worth more than $465,339.78. Insiders at Denali Therapeutics own 7.9% of the company. Learn More about insider trades at Denali Therapeutics.
Information on this page was last updated on 11/7/2024.

Jennifer E. Cook Insider Trading History at Denali Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/6/2024	Sell	1,458	$21.73	$31,682.34	20,038

Jennifer E. Cook Buying and Selling Activity at Denali Therapeutics

Denali Therapeutics Company Overview

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Today's Range

Now: $24.74

$24.65

$25.72

50 Day Range

MA: $27.20

$24.18

$31.58

2 Week Range

Now: $24.74

$14.56

$33.33

Volume

112,533 shs

Average Volume

1,062,831 shs

Market Capitalization

$3.56 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.35

Media Is Mocking Elon, But Wait Until They See This Demo

From Brownstone Research | Ad

Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.

Click here to watch this demo and decide for yourself.